BMS-986466 + adagrasib

BMS-986466 + adagrasib is an investigational oral combination therapy targeting **KRAS G12C-mutant solid tumors**, including non-small cell lung cancer and other advanced solid tumors. - **BMS-986466** is a small molecule inhibitor of **Src homology phosphotyrosyl phosphatase 2 (SHP2)**, a protein that plays a key role in the RAS/MAPK signaling pathway. By inhibiting SHP2, BMS-986466 may reduce growth and spread of KRAS-mutant cancer cells. - **Adagrasib** is a small molecule inhibitor that selectively and irreversibly binds to the **KRAS G12C mutant protein** in its inactive state, interrupting signaling that drives cancer cell proliferation. This combination is being developed to enhance the inhibition of the RAS pathway in tumors with the KRAS G12C mutation[1][2][4][9].